Vanda Pharmaceuticals (VNDA) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing innovative therapies for high unmet medical needs in the biopharmaceutical sector.

• Commercial portfolio includes Fanapt® (schizophrenia, bipolar I), HETLIOZ® (Non-24, SMS), PONVORY® (multiple sclerosis), and NEREUS™ (motion-induced vomiting).

• Pipeline includes additional indications and new drug candidates targeting CNS, dermatology, oncology, and rare diseases.

Financial performance and metrics

• As of December 31, 2025, 59,101,630 shares of common stock were outstanding.

• Common stock last traded at $7.43 per share on February 11, 2026, on NASDAQ under the symbol VNDA.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, with interim investment in short-term, interest-bearing, investment-grade securities or held as cash.